Gastroenterology
Volume 138, Issue 4 , Pages 1225-1230.e3 , April 2010

The Dawn of a New Era: Transforming Our Domestic Response to Hepatitis B & C

  • Hashem El–Serag

      Affiliations

    • Gastroenterology and Hepatology Section, Clinical Epidemiology and Outcomes Division, Baylor College of Medicine, Houston, Texas
    • Corresponding Author InformationReprint requests Address requests for reprints to: Hashen El-Serag, MD, MPH, Baylor College of Medicine, 2002 Holcombe Boulevard (152), Houston, Texas 77584. fax: (713) 748-7349
    • ,
  • Anna S.F. Lok

      Affiliations

    • Clinical Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
    • ,
  • David L. Thomas

      Affiliations

    • Department of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, Maryland

References 

  1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714
  2. Centers for Disease Control and Prevention. Divisions of Viral Hepatitis-Statistics and Surveillance (Disease Burden from Viral Hepatitis A, B, and C in the United States). http://www.cdc.gov/hepatitis/PDFs/disease_burden.pdf2008
  3. Cohen C, Evans AA, London WT, et al. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 2008;15:12–13
  4. Edlin BR, Shu M, Barron-Vaya Y. Five million Americans infected with the hepatitis C virus: a corrected estimate (American Association for The Study of Liver Diseases. November 11–15, 2005 San Francisco). Hepatology. 2005;42(4 suppl 1):213A
  5. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis—US, 2006. MMWR. 2008;57:No. SS–2

 Conflicts of interest The authors disclose no conflicts.

 Funding Support for the 2-day meeting was provided by independent educational grants from Gilead Sciences, Inc, Bristol-Myers Squibb, and Vertex Pharmaceuticals. This activity is supported by independent educational grants provided by Gilead Sciences Inc. and Vertex Pharmaceuticals.

PII: S0016-5085(10)00262-3

doi: 10.1053/j.gastro.2010.02.034

Gastroenterology
Volume 138, Issue 4 , Pages 1225-1230.e3 , April 2010

Article Tools

* Image Usage & Resolution